Pharmaxis Receives $5m R&D Tax Incentive

9th Jan 23

Release Date: 09/01/2023 9:55am

Clinical stage drug developer Pharmaxis Ltd (ASX: PXS) has received a R&D tax incentive of $4,953,337 in relation to the 2022 financial year. The receipt of this incentive and the recently completed placement ($10.0m before expenses) adds to the Company’s cash funds, which were $11.6 million at 30 September 2022.

Read full media release - pdf

Categories: News and Media